Dina Ben-Yehuda
Overview
Explore the profile of Dina Ben-Yehuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
3247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ben-Arye E, Mao J, Bruera E, Samuels N, Keshet Y, Lee R, et al.
J Pain Symptom Manage
. 2023 Sep;
67(1):69-76.
PMID: 37769821
Context And Objectives: To explore the feasibility of implementing the joint guideline on integrative medicine for pain management in oncology, published by the Society for Integrative Oncology (SIO) and the...
2.
Richardson P, Nagler A, Ben-Yehuda D, Badros A, Hari P, Hajek R, et al.
EJHaem
. 2022 Jul;
1(1):94-102.
PMID: 35847734
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity in preclinical studies and encouraging early-phase clinical activity...
3.
Ben-Arye E, Finkelstein A, Samuels N, Ben-Yehuda D, Schiff E, Reis S, et al.
Support Care Cancer
. 2022 Feb;
30(6):4789-4795.
PMID: 35142910
Objective: The present study aimed to explore attitudes of medical students following a course in integrative medicine (IM) focused on palliative and supportive cancer. Method: Attitudes to IM among pre-clerkship...
4.
Samuels N, Shaham D, Schiff E, Ben-Yehuda D, Finkelstein A, Lesser L, et al.
Patient Educ Couns
. 2021 Nov;
105(7):2256-2263.
PMID: 34756637
Objective: To examine the impact of an integrative medicine (IM) course on self-perceived IM-related communication and research skills. Methods: A 3-day mandatory "hybrid" (online and in-person) IM course was held...
5.
Plesner T, Dimopoulos M, Oriol A, San-Miguel J, Bahlis N, Rabin N, et al.
Br J Haematol
. 2021 Apr;
194(1):132-139.
PMID: 33822368
In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamethasone...
6.
Hodkinson B, Schaffer M, Brody J, Jurczak W, Carpio C, Ben-Yehuda D, et al.
Transl Oncol
. 2021 Jan;
14(1):100977.
PMID: 33395752
We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002...
7.
Karavani G, Feigin N, Tachover T, Bdolah-Abram T, Lavie D, Ben-Yehuda D, et al.
Andrologia
. 2020 Aug;
52(10):e13794.
PMID: 32814362
Sperm quality in lymphoma patients may be reduced even prior to initiation of chemotherapy. The objective of this study was to examine the relationship between lymphoma prognostic factors and sperm...
8.
Weisel K, Dimopoulos M, Moreau P, Yagci M, Larocca A, Kanate A, et al.
Leuk Lymphoma
. 2020 Apr;
61(8):1850-1859.
PMID: 32268815
In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or...
9.
Nachmias B, Sandler V, Slyusarevsky E, Pogrebijski G, Kritchevsky S, Ben-Yehuda D, et al.
Ann Hematol
. 2019 Sep;
98(11):2561-2567.
PMID: 31515574
Overt central nervous system (CNS) involvement in aggressive non-Hodgkin's lymphoma (NHL) is rare at diagnosis. Much effort is put to identify risk factors for occult CNS involvement, and the risk...
10.
Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, et al.
Haematologica
. 2019 Jun;
105(1):193-200.
PMID: 31221778
Extramedullary disease is relatively frequent in multiple myeloma, but our knowledge on the subject is limited and mainly relies on small case series or single center experiences. Little is known...